Insider Selling: Icon (NASDAQ:ICLR) Director Sells 10,000 Shares of Stock

Icon Plc (NASDAQ:ICLR – Get Free Report) Director Ciaran Murray sold 10,000 shares of Icon stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $200.18, for a total transaction of $2,001,800.00. Following the completion of the transaction, the director directly owned 7,000 shares of the company’s stock, valued at $1,401,260. This trade represents a 58.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Ciaran Murray also recently made the following trade(s):

  • On Monday, November 2nd, Ciaran Murray sold 3,452 shares of Icon stock. The stock was sold at an average price of $205.66, for a total transaction of $709,938.32.

Icon Stock Performance

ICLR traded down $3.25 on Monday, hitting $191.40. 826,218 shares of the company’s stock were exchanged, compared to its average volume of 1,253,686. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.37. The stock has a fifty day moving average of $179.01 and a two-hundred day moving average of $147.43. Icon Plc has a twelve month low of $66.57 and a twelve month high of $219.04. The firm has a market cap of $14.65 billion, a PE ratio of 32.94, a P/E/G ratio of 10.78 and a beta of 1.19.

Icon (NASDAQ:ICLR – Get Free Report) last issued its earnings results on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. Icon had a return on equity of 7.73% and a net margin of 5.45%. Icon’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.31 earnings per share. On average, research analysts anticipate that Icon Plc will post 9.71 earnings per share for the current fiscal year.

Institutional Trading of Icon

A number of institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Icon during the third quarter valued at approximately $38,000. GAMMA Investing LLC lifted its position in Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after purchasing an additional 69 shares during the period. Parkside Financial Bank & Trust boosted its stake in Icon by 120.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 336 shares in the last quarter. Grove Bank & Trust boosted its stake in Icon by 30.0% during the 2nd quarter. Grove Bank & Trust now owns 866 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 200 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Icon by 1,062.0% during the 1st quarter. Fifth Third Bancorp now owns 918 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 839 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ICLR has been the subject of several analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $254.00 price objective on shares of Icon in a research report on Thursday, October 29th. Barclays raised their target price on Icon from $175.00 to $230.00 and gave the company an “equal weight” rating in a research report on Thursday, October 29th. Truist Financial lifted their target price on Icon from $209.00 to $268.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Weiss Ratings upgraded Icon from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, October 28th. Finally, Robert W. Baird increased their price target on Icon from $210.00 to $249.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Icon currently has a consensus rating of “Moderate Buy” and a consensus price target of $213.76.

Read Our Latest Research Report on ICLR

Icon Company Profile

(Get Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

Featured Stories

Insider Buying and Selling by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.